CN110869027A - 异戊酰螺旋霉素i、ii和/或iii在制备治疗和/或预防肿瘤药物方面的应用和药物 - Google Patents

异戊酰螺旋霉素i、ii和/或iii在制备治疗和/或预防肿瘤药物方面的应用和药物 Download PDF

Info

Publication number
CN110869027A
CN110869027A CN201880019070.8A CN201880019070A CN110869027A CN 110869027 A CN110869027 A CN 110869027A CN 201880019070 A CN201880019070 A CN 201880019070A CN 110869027 A CN110869027 A CN 110869027A
Authority
CN
China
Prior art keywords
tumor
iii
isovaleryl spiramycin
dose groups
compared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880019070.8A
Other languages
English (en)
Other versions
CN110869027B (zh
Inventor
姜恩鸿
赫卫清
戴剑漉
姜洋
姜勋雷
赵小峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenyang Fuyang Pharmaceutical Technology Co Ltd
Original Assignee
Shenyang Fuyang Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Fuyang Pharmaceutical Technology Co Ltd filed Critical Shenyang Fuyang Pharmaceutical Technology Co Ltd
Publication of CN110869027A publication Critical patent/CN110869027A/zh
Application granted granted Critical
Publication of CN110869027B publication Critical patent/CN110869027B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)

Abstract

一种包含异戊酰螺旋霉素I、II和/或III的药物，及其在制备治疗和/或预防肿瘤药物方面的应用。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201880019070.8A 2017-07-04 2018-07-04 异戊酰螺旋霉素i、ii和/或iii在制备治疗和/或预防肿瘤药物方面的应用和药物 Active CN110869027B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN2017105379588 2017-07-04
CN201710537958 2017-07-04
CN201711450396 2017-12-27
CN201711497546 2017-12-27
CN201711450396X 2017-12-27
CN201711450300 2017-12-27
CN2017114975462 2017-12-27
CN201711450300X 2017-12-27
PCT/CN2018/094504 WO2019007368A1 (zh) 2017-07-04 2018-07-04 异戊酰螺旋霉素i、ii和/或iii在制备治疗和/或预防肿瘤药物方面的应用和药物

Publications (2)

Publication Number Publication Date
CN110869027A true CN110869027A (zh) 2020-03-06
CN110869027B CN110869027B (zh) 2023-09-08

Family

ID=64950608

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880019070.8A Active CN110869027B (zh) 2017-07-04 2018-07-04 异戊酰螺旋霉素i、ii和/或iii在制备治疗和/或预防肿瘤药物方面的应用和药物

Country Status (12)

Country Link
US (1) US20200163984A1 (zh)
EP (1) EP3639829B1 (zh)
JP (1) JP7060631B2 (zh)
KR (1) KR102375444B1 (zh)
CN (1) CN110869027B (zh)
AU (1) AU2018298187A1 (zh)
CA (1) CA3068921A1 (zh)
DK (1) DK3639829T3 (zh)
ES (1) ES2912734T3 (zh)
MX (1) MX2019015676A (zh)
RU (1) RU2766176C2 (zh)
WO (1) WO2019007368A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113372397A (zh) * 2021-06-22 2021-09-10 天方药业有限公司 一种己二酸螺旋霉素的制备方法
CN113577086A (zh) * 2020-04-30 2021-11-02 沈阳福洋医药科技有限公司 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2771046C2 (ru) 2018-01-19 2022-04-25 Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. Применение карримицина или его активных ингредиентов
US20200405739A1 (en) * 2018-01-19 2020-12-31 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Mtor inhibitor, pharmaceutical composition and use thereof
CA3142427A1 (en) * 2019-05-16 2020-11-19 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Medicament and combination product used for preventing, alleviating and/or treating fibrosis, and use thereof
US11351185B2 (en) 2020-03-11 2022-06-07 Asclea Corporation Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101568343A (zh) * 2006-06-12 2009-10-28 雷蒙特亚特特拉维夫大学有限公司 用于治疗癌症的方法
CN101785778A (zh) * 2010-03-09 2010-07-28 沈阳同联集团有限公司 异戊酰螺旋霉素i的分离制备及其应用
CN102229634A (zh) * 2010-05-25 2011-11-02 沈阳同联集团有限公司 左旋异戊酰螺旋霉素i、其制剂、制备方法及应用
CN102247396A (zh) * 2010-05-25 2011-11-23 沈阳同联集团有限公司 左旋可利霉素、其药物组合物、制备方法及应用
CN110545820B (zh) * 2017-04-06 2023-01-10 沈阳福洋医药科技有限公司 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1540397A (en) * 1976-12-08 1979-02-14 May & Baker Ltd Spiramycin esters
CA2127578A1 (en) * 1993-07-08 1995-01-09 Keiichi Ajito 16-membered macrolide derivatives and process for producing the same
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
CN101362784A (zh) 2008-10-06 2009-02-11 山东大学 埃博霉素苷类化合物和以其为活性成分的组合物及其应用
CN101773510B (zh) 2010-03-09 2013-06-05 沈阳同联集团有限公司 异戊酰螺旋霉素iii的分离制备
CN101785779B (zh) 2010-03-09 2014-03-05 沈阳同联集团有限公司 异戊酰螺旋霉素ii的分离制备
DK2578595T3 (en) * 2010-05-25 2017-07-10 Shenyang Fuyang Pharmaceutical Tech Co Ltd CRYSTALLINE LEVOISOVALERYL PIRAMYCIN I

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101568343A (zh) * 2006-06-12 2009-10-28 雷蒙特亚特特拉维夫大学有限公司 用于治疗癌症的方法
CN101785778A (zh) * 2010-03-09 2010-07-28 沈阳同联集团有限公司 异戊酰螺旋霉素i的分离制备及其应用
CN102229634A (zh) * 2010-05-25 2011-11-02 沈阳同联集团有限公司 左旋异戊酰螺旋霉素i、其制剂、制备方法及应用
CN102247396A (zh) * 2010-05-25 2011-11-23 沈阳同联集团有限公司 左旋可利霉素、其药物组合物、制备方法及应用
EP2578596A1 (en) * 2010-05-25 2013-04-10 Shenyang Tonglian Group Co., Ltd. Levocarrimycin, pharmaceutical compositions, preparation methods and uses thereof
CN110545820B (zh) * 2017-04-06 2023-01-10 沈阳福洋医药科技有限公司 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113577086A (zh) * 2020-04-30 2021-11-02 沈阳福洋医药科技有限公司 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用
CN113372397A (zh) * 2021-06-22 2021-09-10 天方药业有限公司 一种己二酸螺旋霉素的制备方法

Also Published As

Publication number Publication date
EP3639829A1 (en) 2020-04-22
WO2019007368A1 (zh) 2019-01-10
CA3068921A1 (en) 2019-01-10
RU2766176C2 (ru) 2022-02-08
EP3639829A4 (en) 2020-06-24
RU2020102713A (ru) 2021-08-04
EP3639829B1 (en) 2022-02-09
ES2912734T3 (es) 2022-05-27
DK3639829T3 (da) 2022-05-16
JP7060631B2 (ja) 2022-04-26
US20200163984A1 (en) 2020-05-28
CN110869027B (zh) 2023-09-08
KR102375444B1 (ko) 2022-03-17
AU2018298187A1 (en) 2020-02-06
MX2019015676A (es) 2022-03-17
JP2020528047A (ja) 2020-09-17
KR20200024280A (ko) 2020-03-06
RU2020102713A3 (zh) 2021-08-04

Similar Documents

Publication Publication Date Title
CN110869027B (zh) 异戊酰螺旋霉素i、ii和/或iii在制备治疗和/或预防肿瘤药物方面的应用和药物
CN110545820B (zh) 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用
CN111100006B (zh) 一种3-咖啡酰奎尼酸衍生物及其制备方法和用途
US20170143748A1 (en) Anti-tumor pharmaceutical application of pentacyclic triterpene saponin compounds of szechuan melandium root
CN107362158B (zh) 马钱苷元在制备抗肿瘤药物中的用途
CN113234064B (zh) 一种替加氟衍生物及其制备方法与应用
AU2019254974A1 (en) Drug used for preventing and/or treating pain and/or fever, combination product, and use thereof
CN110384710B (zh) 一种用于预防和/或治疗疼痛的药物、组合产品及其应用
CN109867657B (zh) 二羟二苯并[b,f][1,5]二氧杂辛环类化合物、制备方法及其药用组合物和应用
CN104829679B (zh) 一类水溶性南蛇藤素衍生物及其用途
CN111995629B (zh) 大根香叶衍生物及其药物组合物和其在医药中的用途
CN109350620B (zh) 一种治疗卵巢癌的药物及其用途
CN107684563B (zh) 一种含有美洲大蠊和伊马替尼的药物及其应用
WO2024016142A1 (zh) 佛手柑内酯和槲皮素黄酮的组合物在制备治疗癌症药物中的应用
CN104224801B (zh) 苦玄参苷元ⅰ在制备肿瘤多药耐药逆转剂中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant